Literature DB >> 33098242

Weekly Carboplatin and Paclitaxel for Ovarian Cancer: The "Finer Points".

Franco Muggia1.   

Abstract

Entities:  

Year:  2020        PMID： 33098242      PMCID： PMC7794168          DOI： 10.1002/onco.13572

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  17 in total

1.  Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.

Authors:  Claudio Vernieri; Monica Milano; Alessia Mennitto; Claudia Maggi; Benvenuto Ferrari; Lucia Rinaldi; Roberta Mennitto; Claudia Stefanetti; Barbara Re; Gabriella Mariani; Giulia Bianchi; Giuseppe Capri; Filippo de Braud
Journal:  Breast Cancer Res Treat       Date:  2017-06-14       Impact factor: 4.872

2.  Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.

Authors:  Tamar Safra; Joseph Menczer; Rinat Molho Bernstein; Shulem Shpigel; Dianna Matcejevsky; Moshe J Inbar; Abraham Golan; Dan Grisaru; Tally Levy
Journal:  Gynecol Oncol       Date:  2009-05-14       Impact factor: 5.482

3.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Authors:  Robert F Ozols; Brian N Bundy; Benjamin E Greer; Jeffrey M Fowler; Daniel Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca Baergen
Journal:  J Clin Oncol       Date:  2003-07-14       Impact factor: 44.544

4.  Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

Authors:  Joel Shapiro; J Jan B van Lanschot; Maarten C C M Hulshof; Pieter van Hagen; Mark I van Berge Henegouwen; Bas P L Wijnhoven; Hanneke W M van Laarhoven; Grard A P Nieuwenhuijzen; Geke A P Hospers; Johannes J Bonenkamp; Miguel A Cuesta; Reinoud J B Blaisse; Olivier R C Busch; Fiebo J W Ten Kate; Geert-Jan M Creemers; Cornelis J A Punt; John Th M Plukker; Henk M W Verheul; Ernst J Spillenaar Bilgen; Herman van Dekken; Maurice J C van der Sangen; Tom Rozema; Katharina Biermann; Jannet C Beukema; Anna H M Piet; Caroline M van Rij; Janny G Reinders; Hugo W Tilanus; Ewout W Steyerberg; Ate van der Gaast
Journal:  Lancet Oncol       Date:  2015-08-05       Impact factor: 41.316

5.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Authors:  Michael A Bookman; Mark F Brady; William P McGuire; Peter G Harper; David S Alberts; Michael Friedlander; Nicoletta Colombo; Jeffrey M Fowler; Peter A Argenta; Koen De Geest; David G Mutch; Robert A Burger; Ann Marie Swart; Edward L Trimble; Chrisann Accario-Winslow; Lawrence M Roth
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

6.  Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.

Authors:  John K Chan; Mark F Brady; Richard T Penson; Helen Huang; Michael J Birrer; Joan L Walker; Paul A DiSilvestro; Stephen C Rubin; Lainie P Martin; Susan A Davidson; Warner K Huh; David M O'Malley; Matthew P Boente; Helen Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2016-02-25       Impact factor: 91.245

7.  Weekly Carboplatin and Paclitaxel: A Retrospective Comparison with the Three-Weekly Schedule in First-Line Treatment of Ovarian Cancer.

Authors:  Tamar Safra; Barliz Waissengrin; Talya Levy; Ellie Leidner; Rotem Merose; Diana Matceyevsky; Dan Grisaru; Ido Laskov; Nadav Mishaan; Rotem Shayzaf; Ido Wolf
Journal:  Oncologist       Date:  2020-08-12

8.  Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.

Authors:  Noriyuki Katsumata; Makoto Yasuda; Seiji Isonishi; Fumiaki Takahashi; Hirofumi Michimae; Eizo Kimura; Daisuke Aoki; Toshiko Jobo; Shoji Kodama; Fumitoshi Terauchi; Toru Sugiyama; Kazunori Ochiai
Journal:  Lancet Oncol       Date:  2013-08-13       Impact factor: 41.316

9.  A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan.

Authors:  Hirotoshi Iihara; Mototsugu Shimokawa; Toshinobu Hayashi; Hitoshi Kawazoe; Toshiaki Saeki; Keisuke Aiba; Kazuo Tamura
Journal:  Oncologist       Date:  2019-10-21

10.  Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.

Authors:  Andrew R Clamp; Elizabeth C James; Iain A McNeish; Andrew Dean; Jae-Weon Kim; Dearbhaile M O'Donnell; Jane Hook; Christopher Coyle; Sarah Blagden; James D Brenton; Raj Naik; Tim Perren; Sudha Sundar; Adrian D Cook; Gosala S Gopalakrishnan; Hani Gabra; Rosemary Lord; Graham Dark; Helena M Earl; Marcia Hall; Susana Banerjee; Rosalind M Glasspool; Rachel Jones; Sarah Williams; Ann Marie Swart; Sally Stenning; Mahesh Parmar; Richard Kaplan; Jonathan A Ledermann
Journal:  Lancet       Date:  2019-11-29       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.